Introduction
Overactive bladder (OAB) symptoms are characterized by urinary urgency, frequency, and nocturia with or without incontinence (Abrams et al., 2002) . OAB affects more than 30 million adults in United States (Coyne et al., 2011) . Currently, antimuscarinic drugs are the first-line pharmacotherapy for OAB, but have a limited efficacy with significant adverse effect (Andersson et al., 2003 (Andersson et al., , 2004 Chapple et al., 2008) . If pharmacotherapy fails, sacral neuromodulation is one of the alternative treatment options for OAB. Although this therapy has been approved by the US Food and Drug Administration to treat OAB for more than a decade (Schmidt et al., 1999; van Kerrebroeck et al., 2007) , its mechanism of action is still uncertain (Elkelini et al., 2010) . The initial event in sacral neuromodulation is the activation of primary afferent nerves that project into the spinal cord and trigger the release of neurotransmitters that in turn modulate the neural pathways controlling bladder function.
Unfortunately, little is known about the identity of the neurotransmitters, the receptors that they activate, or their site of action. The present experiments were undertaken to address these issues.
Our previous studies in cat revealed that spinal GABA A receptors play an important role in pudendal neuromodulation of bladder overactivity (Xiao et al., 2014) , while opioid and glycine receptors have no or a minor role (Mally et al., 2013; Rogers et al., 2015) . On the other hand we showed that opioid receptors have an essential role in tibial neuromodulation of bladder overactivity in the cat (Tai et al., 2012) . Because afferent axons passing through the pudendal and tibial nerves enter the spinal cord through the sacral S1-S2 dorsal roots, it is possible that sacral neuromodulation activates these afferents in S1-S2 dorsal roots and might mimic some or all of the effects of pudendal/tibial neuromodulation. Therefore in this study we examined the effects of a GABA A receptor antagonist (picrotoxin), a glycine receptor antagonist (strychnine), and an opioid receptor antagonist (naloxone) on the modulation of J P E T # 2 3 5 8 6 4 5 | P a g e bladder overactivity elicited electrical stimulation of the S1 or S2 sacral dorsal roots.
Methods and Materials
The protocol and animal use in this study were approved by Animal Care and Use
Committee at the University of Pittsburgh.
Surgical procedures
A total of 20 cats (9 males and 11 females, 2.7-5.0 kg; Liberty Research, Waverly, NY) were used in this study. The animals were anesthetized with isoflurane (2-5% in oxygen)
during surgery and then switched to α -chloralose anesthesia (initial 65 mg/kg followed by slow i.v. infusion at 2 mg/kg per hour) during data collection. Pancuronium (initial 0.1 mg/kg followed by slow i.v. infusion at 0.1 mg/kg per hour) was also given during data collection to prevent striated muscle contractions and movement of the animal. Right and left cephalic veins were catheterized for i.v. administration of drugs and fluid. A tracheotomy was performed and a tube was inserted to keep the airway patent. A catheter was inserted into right carotid artery to monitor systemic arterial blood pressure. The mean systemic blood pressure was measured as the average of systolic and diastolic blood pressures. Heart rate and blood oxygen were monitored by a pulse oximeter (9847V; NONIN Medical, Plymouth, MN) attached to the tongue. Through an abdominal incision, the ureters were isolated, tied, and cut for external drainage. A double lumen catheter was inserted through the urethra into the bladder and secured by a ligature around the urethra. One lumen was connected to a pump to slowly (1-3 ml/min) infuse saline or 0.5% acetic acid (AA) in saline. The other lumen was attached to a pressure transducer to measure bladder pressure. After the surgery, the skin and muscle layers were closed by sutures.
The spinal cord and cauda equina were exposed between the L7 and Cx1 vertebrae This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from J  P  E  T  #  2  3  5  8  6  4 6 | P a g e via a dorsal laminectomy. The spinal dura was cut and the S1 and S2 dorsal roots on the right side were separated for electrical stimulation. A bipolar stainless steel hook electrode was used during the experiment to stimulate individual S1/S2 dorsal roots by delivering electrical pulses that were generated by an electrical stimulator (S88, Grass Medical Instruments, Quincy, MA). The animal was mounted in a modified Narishige "Eccles" spinal cord frame in which the hip was supported by metal pins, and the spinous process at the rostral end of the laminectomy was secured with a clamp. The skin, cut mid-sagittally from L4 to S3, was tied along each margin to form a pool that was filled with warmed (35-37°C) mineral oil. The temperature of the animal was maintained at 36-38°C using a heating pad during the experiments. In 5 cats, a small catheter (PE10) was inserted rostrally underneath the dura to position the catheter tip between S1 and S2 spinal cord for i.t. administration of picrotoxin or naloxone. The location of the intrathecal catheter was confirmed by a postmortem laminectomy between the L5-L6 spinal processes.
Stimulation protocol and drug administration
Our previous study in cats (Zhang et al., 2013) showed that reflex bladder activity could be inhibited by electrical stimulation (5 Hz frequency and 0.2 ms pulse width) of S1 or S2 dorsal roots at threshold (T) intensity for inducing reflex twitching of the anal sphincter or toe, while stimulation of S3 dorsal root or S1-S3 ventral roots was not effective. Therefore, stimulation (5 Hz, 0.2 ms) of S1 or S2 dorsal roots at motor threshold intensity was used in this study to inhibit reflex bladder activity. The motor threshold was determined before administering pancuronium.
At the beginning of each experiment, multiple cystometrograms (CMGs) were performed by slowly infusing the bladder with saline to determine the bladder capacity that was defined as the bladder volume threshold to induce a bladder contraction of large given, which was followed by a single dose (0.3 mg in 0.1 mL saline, i.t.) of naloxone. The dosage of each drug is chosen based on our previous studies (Hisamitsu and de Groat, 1984 , Rogers et al., 2015 , Xiao et al., 2014 . After administering each dose of drug, the four CMGs (control, S1 stimulation, S2 stimulation, control) were repeated to determine the drug effects.
A ten minute waiting period for each i.v. dose of picrotoxin or strychnine and a five minute period for i.t. picrotoxin or naloxone were used to allow time for the drugs to take effect. A waiting period of 2-3 minutes was also used between CMGs to allow the bladder reflex to recover. Our previous studies (Rogers et al., 2015 , Xiao et al., 2014 showed that the effects of picrotoxin or strychnine lasted long enough to perform the four repeated CMGs that required about 30-40 minutes.
Data analysis
The bladder capacity was measured from each CMG and normalized to the capacity This article has not been copyedited and formatted. The final version may differ from this version. 
Results

Inhibition of bladder overactivity by S1 or S2 dorsal root stimulation
AA irritation induced bladder overactivity and significantly (p<0.01) reduced bladder capacity to 59.5±4.8% of saline control capacity (N=20 cats, Fig.1 ). S1 or S2 dorsal root stimulation at threshold intensity for inducing reflex twitching of anal sphincter or toe inhibited bladder overactivity and significantly (p<0.01) increased bladder capacity to 105.3±9.0% and 134.8±8.9% of saline control, respectively. After the stimulation, AA control capacity returned to pre-stimulation level, indicating that there was no poststimulation effect (Fig. 1B) .
Effect of i.v. picrotoxin on sacral inhibition of bladder overactivity
Picrotoxin (i.v.) slightly increased the pre-stimulation bladder capacity at 0.3-1.0 mg/kg doses (first column CMGs in Fig.2A ), but the increase was not statistically significant (p>0.05, N=9 cats, Fig.2B ). The 0.3 mg/kg dose of picrotoxin blocked (p<0.05) the increase in bladder capacity elicited by S1 dorsal root stimulation but not the increase elicited by S2 dorsal root stimulation (Fig.2B ). Picrotoxin at 1 mg/kg blocked (p<0.05) the increase in bladder capacity induced by either S1 or S2 dorsal root stimulation (Fig.2B) . After the stimulation, the bladder capacity returned to pre-stimulation level at every dose of picrotoxin, was not changed after any dose of picrotoxin (162.0±4.5 mmHg).
Combined effect of i.v. strychnine and picrotoxin on sacral inhibition of bladder overactivity
Strychnine at 0.03-0.3 mg/kg (i.v.) significantly (p<0.05) increased the prestimulation bladder capacity without affecting the increase in bladder capacity caused by S1
or S2 dorsal root stimulation (N=6 cats, Fig.3 ). Mean systemic blood pressure (control:
154.2±1.8 mmHg) was not changed after any dose of strychnine (150.6±3.8 mmHg).
Following strychnine treatment, picrotoxin (0.3 mg/kg, i.v.) further significantly (p<0.05) increased the pre-stimulation bladder capacity and blocked the inhibition induced by S1 or S2 dorsal root stimulation (N=6 cats, Fig.4 .), while the same dose of picrotoxin without strychnine pre-treatment only blocked the inhibition induced by S1 but not S2 dorsal root stimulation (see Fig.2B ). There was no post-stimulation effect at any dose of the drugs.
Effect of i.t. picrotoxin and naloxone on sacral inhibition of bladder overactivity
Picrotoxin (0.4 mg, i.t.) did not significantly change the pre-stimulation bladder capacity and had no effect on the capacity increase induced by either S1 or S2 dorsal root stimulation (N=5 cats, Fig.5 ). However, after sacral dorsal root stimulation the poststimulation bladder capacity was significantly (p<0.05) increased (about 100%), i.e. the stimulation induced a significant post-stimulation inhibitory effect (Fig.5) . Following picrotoxin treatment, naloxone (0.3 mg, i.t.) significantly (p<0.05) reduced the prestimulation bladder capacity and removed the post-stimulation inhibition induced by sacral dorsal root stimulation (Fig.6 ). However, even after i.t. administration of both picrotoxin and naloxone S1 or S2 dorsal root stimulation still significantly (p<0.05) increased bladder capacity during stimulation (Fig.6 ).
This article has not been copyedited and formatted. The final version may differ from this version. and 6). The latter observation suggests that in anesthetized cats sacral neuromodulation activates a spinal opioid inhibitory pathway which however is suppressed by a tonic GABAergic mechanism. These results suggest that sacral neuromodulation of bladder overactivity is mediated by a complex interplay between multiple transmitter mechanisms at spinal and supraspinal sites.
The involvement of GABA A receptors in sacral neuromodulation is very different from their involvement in pudendal neuromodulation. Our previous study in cats (Xiao et al., 2014) showed that spinal GABA A receptors play a critical role in pudendal inhibition of bladder overactivity because i.t. picrotoxin can completely remove the inhibition. In contrast, our current study indicates that spinal GABA A receptors are not involved in inhibition of bladder overactivity elicited by sacral neuromodulation (Fig.5) . However, this inhibition is bladder overactivity. However, the exact sites of action in the brain still need to be determined in future studies.
The involvement of glycine receptor in sacral neuromodulation is also different from its involvement in pudendal neuromodulation. Our previous study in cats (Rogers et al., 2015) showed that strychnine at low doses (0.001-0.003 mg/kg, i.v.) reduces pudendal inhibition of bladder overactivity and at a high dose (0.3 mg/kg, i.v.) unmasks a post-stimulation excitatory effect on the overactive bladder reflex. However, in this study strychnine (i.v.) did not change the inhibition of bladder overactivity elicited by sacral neuromodulation and did not cause post-stimulation excitation (Fig.3) . Instead, strychnine (0.3 mg/kg, i.v.) reduced the intravenous dosage of picrotoxin from 1 mg/kg to 0.3 mg/kg necessary to completely eliminate sacral inhibition of bladder overactivity ( Fig.2 and Fig.4) , indicating a synergistic interaction between glycine and GABA A mechanisms. Please note that the 0.3 mg/kg of picrotoxin is a cumulative dose in Fig.2 but it is a single dose in Fig.4 which includes the data for the interaction between strychnine and picrotoxin.
Due to the pharmacokinetics of the drug, a cumulative dose may not be exactly same as the single dose. However, the different dosing methods should produce similar effects in this study because: 1. a logarithmic increase of the drug dosage was used which allowed an overlap of the effects of the two largest doses of the drug; 2. our previous study (Xiao et al., 2014) showed that the effect of picrotoxin can last more than 50 minutes for the period of performing the 4 repeated CMGs. A better designed dosing study is warranted to further determine the interaction between GABA A and glycine mechanisms.
It is known that inhibitory interneurons in the spinal cord can synthesize and release GABA and glycine as inhibitory co-transmitters (Todd et al., 1996) . A previous study in cat (Thomson and Franz, 1981) by glycine and GABA (Araki, 1994) . However, the interaction between glycine and GABA mechanisms revealed in this study probably occurs in the brain rather than in the spinal cord, because spinal GABA A receptors do not contribute to sacral inhibition of bladder overactivity ( This study only tested a single drug (picrotoxin or strychnine) for each neurotransmitter mechanism. Further testing of different drugs is needed to confirm the results of this study and eliminate possible nonspecific effects related to testing a single drug.
In addition, the small number of cats in each drug test (6 or 9 cats/group) cannot determine the variability related to sex, size, and age of the animals. More studies are certainly needed to further examine these issues.
In summary, comparing this study of sacral neuromodulation to previous studies of pudendal or tibial neuromodulation showed that the GABA A and glycine mechanisms are involved differently in sacral and pudendal neuromodulation, while the post-stimulation inhibition induced by either sacral or tibial neuromdolation under different conditions is mediated by the same neurotransmitter (opioid) mechanism. These results suggest that the mechanisms underlying sacral neuromodulation could be different from pudendal/tibial neuromoduation, but at the same time they may also share some properties. Understanding neurotransmitter mechanisms involved in sacral neuromodulation could further improve this effective OAB treatment and identify molecular targets for developing new treatments for OAB. Repeated CMGs were performed during acetic acid (AA) infusion with or without S1 or S2
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